相似文献
1
MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.
Ther Adv Neurol Disord. 2017 Jun;10(6):247-261. doi: 10.1177/1756285617708911. Epub 2017 May 12.
2
Imaging Markers for Monitoring Disease Activity in Multiple Sclerosis.
Curr Treat Options Neurol. 2017 May;19(5):18. doi: 10.1007/s11940-017-0453-6.
3
MRI in the Diagnosis and Monitoring of Multiple Sclerosis: An Update.
Clin Neuroradiol. 2015 Oct;25 Suppl 2:157-65. doi: 10.1007/s00062-015-0430-y. Epub 2015 Jul 23.
4
[A current view on the MRI diagnosis of multiple sclerosis: an update of 2016 revised MRI criteria].
Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(2. Vyp. 2):66-73. doi: 10.17116/jnevro20171172266-73.
5
Application of the McDonald MRI criteria in multiple sclerosis.
Ann Acad Med Singap. 2007 Aug;36(8):647-54.
6
Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study.
Lancet Neurol. 2018 Feb;17(2):133-142. doi: 10.1016/S1474-4422(17)30469-6. Epub 2017 Dec 21.
7
A comparison of sagittal short T1 inversion recovery and T2-weighted FSE sequences for detection of multiple sclerosis spinal cord lesions.
Acta Neurol Scand. 2014 Mar;129(3):198-203. doi: 10.1111/ane.12168. Epub 2013 Aug 28.
8
Applicability of McDonald 2010 and Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) 2016 Magnetic Resonance Imaging Criteria for the Diagnosis of Multiple Sclerosis in Sri Lanka.
J Clin Neurol. 2018 Jul;14(3):339-344. doi: 10.3988/jcn.2018.14.3.339. Epub 2018 May 31.
9
[Magnetic Resonance Imaging of Multiple Sclerosis].
Brain Nerve. 2020 May;72(5):493-508. doi: 10.11477/mf.1416201553.
10
MRI in multiple sclerosis: what is changing?
Curr Opin Neurol. 2018 Aug;31(4):386-395. doi: 10.1097/WCO.0000000000000572.
引用本文的文献
1
Brain Atrophy and Cognitive Impairment in Primary and Secondary Progressive Multiple Sclerosis Cohort-Similar Progressive MS Phenotype.
Int J Mol Sci. 2025 Sep 2;26(17):8523. doi: 10.3390/ijms26178523.
2
Updates in pelvic neuromodulation: the role of pelvic neuromodulation in pelvic disorders.
Front Urol. 2024 Mar 15;4:1329305. doi: 10.3389/fruro.2024.1329305. eCollection 2024.
3
Validation of a semi-automated method to quantify lesion volume changes in multiple sclerosis on 2D proton-density-weighted scans based on image subtraction.
Neuroimage Rep. 2023 Dec 21;4(1):100194. doi: 10.1016/j.ynirp.2023.100194. eCollection 2024 Mar.
4
Effectiveness of Ocrelizumab on Disease Progression and Disability Status in Multiple Sclerosis Patients: A Two-Year Prospective Cohort Study.
J Clin Med. 2025 Jan 16;14(2):553. doi: 10.3390/jcm14020553.
5
Magnetic resonance imaging-based biomarkers of multiple sclerosis and neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.
J Neurol. 2024 Dec 16;272(1):77. doi: 10.1007/s00415-024-12827-x.
6
Exploring Spinal Cord Changes in Multiple Sclerosis Patients Using MRI.
NeuroSci. 2024 Mar 12;5(1):87-97. doi: 10.3390/neurosci5010006. eCollection 2024 Mar.
7
Super-Resolution in Clinically Available Spinal Cord MRIs Enables Automated Atrophy Analysis.
AJNR Am J Neuroradiol. 2025 Apr 2;46(4):823-831. doi: 10.3174/ajnr.A8526.
8
Ultrafast Brain MRI at 3 T for MS: Evaluation of a 51-Second Deep Learning-Enhanced T2-EPI-FLAIR Sequence.
Diagnostics (Basel). 2024 Aug 23;14(17):1841. doi: 10.3390/diagnostics14171841.
9
Revolutionizing Neurology: The Role of Artificial Intelligence in Advancing Diagnosis and Treatment.
Cureus. 2024 Jun 5;16(6):e61706. doi: 10.7759/cureus.61706. eCollection 2024 Jun.
10
Advanced MRI Techniques: Diagnosis and Follow-Up of Multiple Sclerosis.
Diagnostics (Basel). 2024 May 28;14(11):1120. doi: 10.3390/diagnostics14111120.
本文引用的文献
1
The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative.
Nat Rev Neurol. 2016 Dec;12(12):714-722. doi: 10.1038/nrneurol.2016.166. Epub 2016 Nov 11.
2
g-Ratio weighted imaging of the human spinal cord in vivo.
Neuroimage. 2017 Jan 15;145(Pt A):11-23. doi: 10.1016/j.neuroimage.2016.09.018. Epub 2016 Sep 22.
3
Spinal Cord in Multiple Sclerosis: Magnetic Resonance Imaging Features and Differential Diagnosis.
Semin Ultrasound CT MR. 2016 Oct;37(5):396-410. doi: 10.1053/j.sult.2016.05.005. Epub 2016 May 6.
4
Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy.
Mult Scler. 2017 May;23(6):830-835. doi: 10.1177/1352458516667241. Epub 2016 Sep 6.
5
The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
Neurology. 2016 Sep 27;87(13):1393-9. doi: 10.1212/WNL.0000000000003152. Epub 2016 Aug 31.
6
MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.
J Neurol Neurosurg Psychiatry. 2016 Oct;87(10):1138-45. doi: 10.1136/jnnp-2016-313772. Epub 2016 Aug 16.
7
A Comparison of Magnetization Transfer Methods to Assess Brain and Cervical Cord Microstructure in Multiple Sclerosis.
J Neuroimaging. 2017 Mar;27(2):221-226. doi: 10.1111/jon.12377. Epub 2016 Aug 5.
8
Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome.
Mult Scler. 2017 Apr;23(5):665-674. doi: 10.1177/1352458516663034. Epub 2016 Aug 6.
9
Long-term evolution of multiple sclerosis disability in the treatment era.
Ann Neurol. 2016 Oct;80(4):499-510. doi: 10.1002/ana.24747. Epub 2016 Aug 13.
10
Magnetic Susceptibility from Quantitative Susceptibility Mapping Can Differentiate New Enhancing from Nonenhancing Multiple Sclerosis Lesions without Gadolinium Injection.
AJNR Am J Neuroradiol. 2016 Oct;37(10):1794-1799. doi: 10.3174/ajnr.A4856. Epub 2016 Jun 30.
Zotero 插件